mRNA-1273

mRNA-1273
Name	mRNA-1273
Type	Messenger RNA vaccine
Target	SARS-CoV-2
Disease	COVID-19
Manufacturer	Moderna
Routes of administration	Intramuscular injection

mRNA-1273 is a messenger RNA-based vaccine developed to confer protection against COVID-19, the disease caused by the SARS-CoV-2 virus. It was created by the biotechnology company Moderna in collaboration with the National Institute of Allergy and Infectious Diseases under the direction of Anthony Fauci. The vaccine's rapid development and deployment were central to the global pandemic response, utilizing a novel platform that instructs human cells to produce the viral spike protein to elicit an immune response.

Background and development

The foundational technology for this vaccine platform originated from decades of research into mRNA therapeutics, with key advancements made by scientists like Katalin Karikó and Drew Weissman. The COVID-19 pandemic, declared by the World Health Organization in March 2020, triggered an unprecedented global effort under initiatives like Operation Warp Speed. Researchers at Moderna and the Vaccine Research Center at the National Institutes of Health rapidly designed the vaccine sequence based on the genetic code of the SARS-CoV-2 virus published by authorities in China. The development leveraged prior work on Middle East respiratory syndrome-related coronaviruses and was financially supported by the Biomedical Advanced Research and Development Authority.

Clinical trials and efficacy

The clinical development program proceeded through a series of phased trials. The Phase I trial, led by investigators at the Kaiser Permanente Washington Health Research Institute, demonstrated promising immunogenicity. The pivotal Phase III trial, known as the COVE study, enrolled over 30,000 participants across the United States and was conducted in collaboration with the National Institute of Allergy and Infectious Diseases. Results published in *The New England Journal of Medicine* showed approximately 94% efficacy in preventing symptomatic COVID-19. Subsequent studies, including those monitoring variants like Delta and Omicron, indicated strong protection against severe disease, hospitalization, and death, though efficacy against mild infection waned over time.

Manufacturing and distribution

Large-scale production was scaled up through a complex global supply chain involving partners like Lonza and Rovi. The vaccine requires storage at ultra-cold chain temperatures, initially at -20°C, which posed significant logistical challenges for distribution, particularly in low-resource settings. Distribution in the United States was managed by the Centers for Disease Control and Prevention in conjunction with state health departments like the California Department of Public Health. Global allocation was coordinated through mechanisms like COVAX, with doses shipped to countries including Canada, the United Kingdom, and South Korea.

Mechanism of action

The vaccine utilizes a nucleoside-modified mRNA sequence encapsulated in lipid nanoparticles. Upon intramuscular injection by a healthcare professional, these nanoparticles deliver the mRNA into host cells, primarily at the deltoid muscle site. The cellular machinery, namely ribosomes, then translates the mRNA to produce the SARS-CoV-2 spike protein. This protein, which is non-infectious, is displayed on the cell surface, triggering recognition by the immune system. This process stimulates the production of neutralizing antibodies by B cells and activates T cells, creating a memory immune response that prepares the body to fight future infection by the actual virus.

Safety profile and adverse events

The safety data from the COVE study and extensive post-authorization monitoring have established a well-characterized profile. Common adverse reactions are typically mild to moderate and include injection site pain, fatigue, headache, myalgia, and chills, resolving within a few days. Rare but serious events identified include myocarditis and pericarditis, observed predominantly in younger males after the second dose. Surveillance systems like the Vaccine Adverse Event Reporting System in the U.S. and the European Medicines Agency's EudraVigilance continuously monitor safety. The overall benefit-risk profile remains overwhelmingly positive, with the vaccine preventing vast numbers of severe outcomes from COVID-19.

Regulatory approval and authorization

The vaccine first received an Emergency Use Authorization from the U.S. Food and Drug Administration in December 2020, following a positive review by its Vaccines and Related Biological Products Advisory Committee. Conditional marketing authorization was subsequently granted by the European Medicines Agency and other regulators worldwide, including Health Canada and the Medicines and Healthcare products Regulatory Agency in the United Kingdom. Full licensure, under the brand name Spikevax, was granted by the FDA in January 2022 for use in adults. Recommendations for its use, including primary series and booster doses, are issued by advisory bodies like the Advisory Committee on Immunization Practices and the World Health Organization's Strategic Advisory Group of Experts on Immunization.

Category:COVID-19 vaccines Category:Messenger RNA vaccines Category:Moderna